Prolonged adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 2.
Eleven hundred and sixteen primary female breast cancer patients received one short perioperative chemotherapy course. The node negative patients were randomised between immunotherapy (corynebacterium parvum s.c. around the scar 2 weeks after mastectomy), or no further adjuvant therapy. A moderate, but significant delaying effect was observed, without side effects. The node positive patients were randomised to four groups: 1) the same immunotherapy as in the node negative patients, 2) CMF for 1 year, 3) combination of these two treatments, or 4) no further adjuvant therapy. The prolonged chemotherapy had a significant positive effect, but also considerable and distressing side effects. The immunotherapy had a non-significant negative effect in the node positive patients, but without side effects.
Nissen-Meyer
R
R
Høst
H
H
Kjellgren
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D015411:Mastectomy, Modified Radical; D008727:Methotrexate / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate